A SYSTEMATIC REVIEW WITH META-ANALYSIS OF THE SAFETY OF JANUS KINASE INHIBITORS IN RELATION TO THE RISKS OF SECONDARY BACTERIAL INFECTIONS


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Janus kinase (JAK) inhibitors are included in both domestic and a number of international guidelines for novel coronavirus infection treatment. In order to assess the safety of the use of this class of drugs for preventive pathogenetic therapy of COVID-19, a systematic review with a metaanalysis of the results was carried out. Material and methods. Using queries in international and Russian databases, we searched for controlled trials of baricitinib and tofacitinib recommended for use in Russia as a preventive therapy for COVID-19 mild and moderate clinical cases. Result. Data were obtained from three randomized clinical trials. A meta-analysis of their results regarding the total number of serious adverse events and adverse events belonging to the class «Infections and invasions» showed statistically significant data on the greater safety of baricitinib and tofacitinib in relation to the risks of these events compared with standard therapy. The risk ratio for serious adverse events in the control groups was 0,82 (95% CI: 0,69-0,96; p=0,02), the risk ratio for «Infections and invasions» was 0,78 (95% CI: 0,63-0,97, p=0,03); in both cases the result was in favor of the use of JAK inhibitors. Conclusion. Performing of various design studies in a wider patient population will allow to make more accurate assessment of the risks of developing secondary bacterial infections against the background of short-term use of JAK inhibitors as part of the preventive pathogenetic therapy for COVID-19.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Yuliya Gomon

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia; Hospital of St. George the Great Martyr

Email: gomonmd@yandex.ru
Dr. med. habil., professor of the Department of clinical pharmacology and evidence-based medicine; clinical pharmacologist 197022, Saint Petersburg, 6-8 Lva Tolstogo Str

Alexey Kolbin

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia; Saint Petersburg State University

Email: alex.kolbin1971@gmail.com
Dr. med. habil., professor, head of the Department of clinical pharmacology and evidence-based medicine; professor of the Department of pharmacology of the medical faculty 197022, Saint Petersburg, 6-8 Lva Tolstogo Str

Valery Strizheletsky

Saint Petersburg State University; Hospital of St. George the Great Martyr

Email: b4@zdrav.spb.ru
Dr. med. habil., professor of the Department of faculty surgery of the Faculty of medicine; chief physician 194354, Saint Petersburg, 1 Severny Avenue

Igor Ivanov

Saint Petersburg State University; Hospital of St. George the Great Martyr

Email: b4@zdrav.spb.ru
assistant at the Department of propaedeutics of internal diseases of the Faculty of medicine; deputy chief physician 194354, Saint Petersburg, 1 Severny Avenue

Flora Sultanova

Hospital of St. George the Great Martyr

Email: b4@zdrav.spb.ru
surgeon 194354, Saint Petersburg, 1 Severny Avenue

Yuliya Balykina

Saint Petersburg State University

Email: julia.balykina@gmail.com
PhD in physics and mathematics, associate professor of the Department of mathematical modeling of energy systems of the Faculty of applied mathematics and control processes 198504, Saint Petersburg 35 Universitetsky Avenue

Elena Verbitskaya

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

Email: elena.verbitskaya@gmail.com
PhD in biology, associate professor, associate professor of the Department of clinical pharmacology and evidence-based medicine 197022, Saint Petersburg, 6-8 Lva Tolstogo Str

Әдебиет тізімі

  1. Meyer N.J., Gattinoni L., Calfee C.S. Acute respiratory distress syndrome. Lancet. 2021; 398(10300): 622-37. https://dx.doi.org/10.1016/S0140-6736(21)00439-6.
  2. Camporota L., Chiumello D., Busana M. et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome. Lancet Respir Med. 2021; 9(1): e1. https://dx.doi.org/10.1016/S2213-2600(20)30505-1.
  3. Babon J.J., Lucet I.S., Murphy J.M. et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014; 462(1): 1-13. https://dx.doi.org/10.1042/BJ20140712.
  4. Bousoik E., Montazeri Aliabadi H. «Do We Know Jack» about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol. 2018; 8: 287. https://dx.doi.org/10.3389/fonc.2018.00287.
  5. Zhang W., Zhao Y., Zhang F. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020; 214: 108393. https://dx.doi.org/10.1016/j. clim.2020.108393.
  6. Stebbing J., Phelan A., Griffin I. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20(4): 400-2. https://dx.doi.org/10.1016/S1473-3099(20)30132-8
  7. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 14 (27.12.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/ original/ВМP_COVID-19_V14_27-12-2021 .pdf (дата обращения - 10.04.2022)
  8. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. URL: https://www.covid19treatmentguidelines.nih.gov (date of access - 10.04.2022)
  9. Agarwal A., Rochwerg B., Lamontagne F. et al. A living WHO guideline on drugs for Covid-19. BMJ. 2020; 370: m3379. https://dx.doi.org/10.1136/bmj.m3379
  10. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of baricitinib. 2021. URL: https://www.fda.gov/media/143823/download (date of access - 10.04.2022)
  11. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death (date of access - 10.04.2022)
  12. Penman S., Kiy R.T., Jensen R.L. et al. Safety perspectives on presently considered drugs for the treatment of COVID-19. Br J Pharmacol. 2020; 177(19): 4353-74. https://dx.doi.org/10.1111/bph.15204
  13. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru (дата обращения 10.04.2022)
  14. Реброва О.Ю., Федяева В.К., Хачатрян Г.Р. Адаптация и валидизация вопросника для оценки риска систематических ошибок в рандомизированных контролируемых испытаниях. Медицинские технологии. Оценка и выбор. 2015; 1: 9-17
  15. Реброва О.Ю., Федяева В.К. Вопросник для оценки риска систематических ошибок в нерандомизированных сравнительных исследованиях: русскоязычная версия шкалы Ньюкасл-Оттава. Медицинские технологии. Оценка и выбор. 2016; 3: 14-19
  16. Cantini F., Niccoli L., Nannini C. et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020; 81(4): 647-79. https://dx.doi.org/10.1016/j.jinf.2020.06.052.
  17. Hasan M.J., Rabbani R., Anam A.M. et al. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh. BMC Infect Dis. 2021; 21(1): 427. https://dx.doi.org/10.1186/s12879-021-06119-2.
  18. Iglesias Gomez R., Mendez R., Palanques-Pastor T. et al. Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. Eur J Hosp Pharm. 2021: ejhpharm-2021-002741. https://dx.doi.org/10.1136/ejhpharm-2021-002741.
  19. Titanji B.K., Farley M.M., Mehta A. et al. Use of baricitinib in patients with moderate to severe coronavirus disease 2019. Clin Infect Dis. 2021; 72(7): 1247-50. https://dx.doi.org/10.1093/cid/ciaa879.
  20. Hasan M.J., Rabbani R., Anam A.M., Huq S.M.R. Additional baricitinib loading dose improves clinical outcome in COVID-19. Open Med (Wars). 2020; 16(1): 41-46. https://dx.doi.org/10.1515/med-2021-0010.
  21. Abizanda P., Calbo Mayo J.M., Mas Romero M. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021; 69(10): 2752-58. https://dx.doi.org/10.1111/jgs.17357.
  22. Hayek M.E., Mansour M., Ndetan H. et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes. 2021; 5(3): 605-13. https://dx.doi.org/10.1016/j.mayocpiqo.2021.03.007.
  23. Singh P.K., Lalwani L.K., Govindagoudar M.B. et al. Tofacitinib associated with reduced intubation rates in the management of severe COVID-19 pneumonia: A preliminary experience. Indian J Crit Care Med. 2021; 25(10): 1108-12. https://dx.doi.org/10.5005/jp-journals-10071-23964.
  24. Моисеев С.В., Буланов Н.М., Зыкова А.С. с соавт. Эффективность и безопасность тофацитиниба у пациентов с COVID-19: многоцентровое нерандомизированное контролируемое исследование. Клиническая фармакология и терапия. 2021; 2: 22-30. https://dx.doi.org/10.32756/0869-5490-2021-2-22-30
  25. Kalil A.C., Patterson T.F., Mehta A.K. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021; 384(9): 795-807. https://dx.doi.org/10.1056/NEJMoa2031994.
  26. Marconi V.C., Ramanan A.V., de Bono S. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9(12): 1407-18. https://dx.doi.org/10.1016/S2213-2600(21)00331-3. Erratum in: Lancet Respir Med. 2021; 9(10): e102.
  27. Garcia-Garcia J.A., Perez-Quintana M., Ramos-Giraldez C. et al. Anakinra versus baricitinib: Different strategies for patients hospitalized with COVID-19. J Clin Med. 2021; 10(17): 4019. https://dx.doi.org/10.3390/jcm10174019.
  28. Guimaraes P.O., Quirk D., Furtado R.H. et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021; 385(5): 406-15. https://dx.doi.org/10.1056/NEJMoa2101643.
  29. Allen E.N., Chandler C.I., Mandimika N., Leisegang C, Barnes K. Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst Rev. 2018; 1(1): MR000039. https://dx.doi.org/10.1002/14651858.MR000039.pub2.
  30. Фармаконадзор. Под общ. ред. А.С. Колбина, С.К. Зырянова, Д.Ю. Белоусова, О.А. Логиновской. 2-е изд. (дополненное). М.: 99 Издательство ОКИ: Буки Веди. 2022; 256 с. ISBN: 978-5-4465-2373-3.
  31. Charan J., Dutta S., Kaur R. et al. Tocilizumab in COVID-19: A study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021; 20(9): 1125-36. https://dx.doi.org/10.1080/14740338.2021.1946513.
  32. Jung S.Y., Kim M.S., Li H. et al. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clin Transl Sci. 2022; 15(2): 501-13. https://dx.doi.org/10.1111/cts.13168.
  33. Kim M.S., Jung S.Y., Lee S.W. et al. Hepatobiliary adverse drug reactions associated with remdesivir: The WHO international pharmacovigilance study. Clin Gastroenterol Hepatol. 2021; 19(9): 1970-72.e3. https://dx.doi.org/10.1016/j.cgh.2021.04.039.
  34. Gerard A.O., Laurain A., Fresse A. et al. Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database. Clin Pharmacol Ther. 2021; 109(4): 1021-24. https://dx.doi.org/10.1002/cpt.2145.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>